Ribi ImmunoChem Research Inc. and Xytronyx Inc. havecompleted private placements of common stock, and ClinicalTechnologies Associates Inc. has filed for an offering.
D. Blech & Co. Inc. plans to invest $6 million in Ribi, theHamilton, Mont., developer of immunostimulants, for 2 millionshares of common stock. The multistage deal would give Blech21 percent of Ribi stock (NASDAQ:RIBI).
Xytronyx of San Diego has raised $3.7 million through theplacement of 107,094 units at $35 per unit to a group ofinternational institutional investors. The units consist of twoshares of common stock and one warrant to purchase one shareat $22.50 per share. The company (AMEX:XYX), which makes aperiodontal diagnostic, now has 3.4 million shares of stockoutstanding.
Clinical Technologies, of Elmsford, N.Y., which is developing oraldrug delivery technology, has filed to offer 625,000 to 897,000shares of common stock (NASDAQ:CTAI) at $8 per sharethrough Vector Securities International Inc. The offering willbe made to institutional or other accredited investors.Following the offering, the company will have 4.3 millionshares of stock outstanding.
In other financial news, Cephalon Inc. has filed to increase itsproposed initial public offering to 3.3 million shares from 2.3million shares. The offering price of between $17 and $19 pershare is unchanged. Cephalon, which is focused onneurodegenerative disorders, will have 8.6 million shares ofstock outstanding after the offering. -- KB
(c) 1997 American Health Consultants. All rights reserved.